DK4313058T3 - Sammensætning indeholdende roginolisib og doseringsregime til behandling af kræft eller en inflammatorisk eller autoimmun sygdom - Google Patents

Sammensætning indeholdende roginolisib og doseringsregime til behandling af kræft eller en inflammatorisk eller autoimmun sygdom Download PDF

Info

Publication number
DK4313058T3
DK4313058T3 DK22719266.3T DK22719266T DK4313058T3 DK 4313058 T3 DK4313058 T3 DK 4313058T3 DK 22719266 T DK22719266 T DK 22719266T DK 4313058 T3 DK4313058 T3 DK 4313058T3
Authority
DK
Denmark
Prior art keywords
roginolisib
inflammatory
composition containing
autoimmune disease
treating cancer
Prior art date
Application number
DK22719266.3T
Other languages
Danish (da)
English (en)
Inventor
Catherine Pickering
Der Veen Lars Van
Michael Lahn
Rebeca Zorrilla
Zoë Johnson
Original Assignee
Ionctura Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura Sa filed Critical Ionctura Sa
Application granted granted Critical
Publication of DK4313058T3 publication Critical patent/DK4313058T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
DK22719266.3T 2021-03-29 2022-03-29 Sammensætning indeholdende roginolisib og doseringsregime til behandling af kræft eller en inflammatorisk eller autoimmun sygdom DK4313058T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (1)

Publication Number Publication Date
DK4313058T3 true DK4313058T3 (da) 2025-05-12

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22719266.3T DK4313058T3 (da) 2021-03-29 2022-03-29 Sammensætning indeholdende roginolisib og doseringsregime til behandling af kræft eller en inflammatorisk eller autoimmun sygdom

Country Status (17)

Country Link
US (2) US12605389B2 (cg-RX-API-DMAC7.html)
EP (2) EP4313058B1 (cg-RX-API-DMAC7.html)
JP (1) JP7839803B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022251843B2 (cg-RX-API-DMAC7.html)
CA (1) CA3212731A1 (cg-RX-API-DMAC7.html)
DK (1) DK4313058T3 (cg-RX-API-DMAC7.html)
ES (1) ES3031295T3 (cg-RX-API-DMAC7.html)
FI (1) FI4313058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250516T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071610T2 (cg-RX-API-DMAC7.html)
LT (1) LT4313058T (cg-RX-API-DMAC7.html)
MX (1) MX2023011442A (cg-RX-API-DMAC7.html)
PL (1) PL4313058T3 (cg-RX-API-DMAC7.html)
PT (1) PT4313058T (cg-RX-API-DMAC7.html)
RS (1) RS66754B1 (cg-RX-API-DMAC7.html)
SI (1) SI4313058T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022207646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184266A1 (en) * 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005518A (es) 2009-11-13 2012-06-19 Merck Serono Sa Derivados de pirazol amina triciclica.
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Also Published As

Publication number Publication date
CA3212731A1 (en) 2022-10-06
US20260224587A1 (en) 2026-08-06
PT4313058T (pt) 2025-06-02
LT4313058T (lt) 2025-05-26
RS66754B1 (sr) 2025-05-30
AU2022251843B2 (en) 2026-04-09
HRP20250516T1 (hr) 2025-06-20
SI4313058T1 (sl) 2025-07-31
EP4744651A2 (en) 2026-05-20
ES3031295T3 (en) 2025-07-07
US20240058351A1 (en) 2024-02-22
HUE071610T2 (hu) 2025-09-28
PL4313058T3 (pl) 2025-06-23
FI4313058T3 (fi) 2025-04-30
MX2023011442A (es) 2023-10-18
JP2024518685A (ja) 2024-05-02
AU2022251843A1 (en) 2023-10-05
EP4313058B1 (en) 2025-03-05
WO2022207646A1 (en) 2022-10-06
JP7839803B2 (ja) 2026-04-02
EP4313058A1 (en) 2024-02-07
US12605389B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
DK3818086T3 (da) Behandling og forebyggelse af cancer under anvendelse af HER3-antigenbindende molekyler
DK3713554T3 (da) Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdomme
DK4126066T3 (da) Sammensætninger og fremgangsmåder til behandling af muskeldystrofi
CO2020001823A2 (es) Conjugados de citoquina para el tratamiento de enfermedades autoinmunes
DK3963021T3 (da) Stabiliserede fluorolefinsammensætninger og fremgangsmåder til anvendelse deraf
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3402491T3 (da) Sammensætninger og fremgangsmåder angående flermodale terapeutiske cellesystemer for kræftindikationer
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
IL285631A (en) Methods for producing autologous t cells useful to treat cancers and compositions thereof
CY1126020T1 (el) Κ1ναζολινονες ως αναστολεις parp14
DK4058474T3 (da) Sammensætninger og fremgangsmåder til behandling af egfr-positive kræftformer
DK3773689T5 (da) Antigene peptider til forebyggelse og behandling af kræft
DK3781171T3 (da) Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
DK3634125T3 (da) System og fremgangsmåde til kontrolleret transport af biologiske prøver
DK3817757T3 (da) Peptid-deficient mhc-klasse-i/chaperon-sammensætninger og fremgangsmåder
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
DK4125842T3 (da) Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK3471722T3 (da) Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
DK3886917T3 (da) Kobbernanoklynger, sammensætning omfattende samme og behandling af neurodegenerative sygdomme
DK4284512T3 (da) Sammensætninger og fremgangsmåder til behandling af cytokinfrigivelsessyndrom